Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-10

AUTHORS

Francesco Boccardo, Alessandra Rubagotti, Giario Conti, Domenico Potenzoni, Antonio Manganelli, Demetrio Del Monaco

ABSTRACT

OBJECTIVE: A randomized multicenter (14 centers) trial was conducted in 114 men with prostate cancer to determine whether the antiestrogen tamoxifen ('Nolvadex') 20 mg or the aromatase inhibitor anastrozole ('Arimidex') 1 mg prevent gynecomastia and breast pain during treatment with the non-steroidal antiandrogen bicalutamide ('Casodex') 150 mg, without compromising efficacy, safety, or quality of life. Plasma samples were collected in a subgroup of these patients to investigate whether trough (pre-dose) concentrations of bicalutamide 150 mg are influenced by concomitant administration of tamoxifen 20 mg or anastrozole 1 mg; the results of this pilot study are reported in this article. METHODS: A subpopulation of patients from a randomized placebo-controlled trial evaluating tamoxifen 20 mg and anastrozole 1 mg for the prevention of gynecomastia and breast pain in men receiving bicalutamide 150 mg for early or recurrent prostate cancer were selected on a voluntary basis from three of the trial centers. Plasma samples were collected on days 7, 14, 28, and 84 of therapy and analyzed to determine the plasma concentrations of (R)-bicalutamide and (S)-bicalutamide. In addition, plasma concentrations of tamoxifen, N-desmethyltamoxifen, and anastrozole were determined. RESULTS: A total of 21 patients were selected. There was no significant difference between treatment groups with respect to the trough plasma concentrations of either bicalutamide enantiomer at any point during the study. Plasma concentrations of the enantiomers, and the relative proportion of the (R))- and (S)-enantiomers, were consistent with those reported in previous studies. Plasma concentrations of tamoxifen, N-desmethyltamoxifen, and anastrozole were also similar to those described elsewhere in the literature. CONCLUSIONS: The findings of this pilot study suggest that trough plasma concentrations of bicalutamide enantiomers following administration of bicalutamide 150 mg are not markedly influenced by concomitant administration of tamoxifen 20 mg or anastrozole 1 mg. However, an effect of tamoxifen on bicalutamide pharmacokinetics can not be completely excluded due to the size of this study. Further studies are needed to clarify the effect of tamoxifen on bicalutamide pharmacokinetics and prostate cancer control in bicalutamide-treated patients. 'Arimidex', 'Casodex', and 'Nolvadex' are trademarks of the AstraZeneca group of companies. More... »

PAGES

415-420

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-005-1016-1

DOI

http://dx.doi.org/10.1007/s00280-005-1016-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1008917393

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15838655


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anastrozole", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Androgen Antagonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anilides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Hormonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aromatase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chromatography, High Pressure Liquid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Interactions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gynecomastia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nitriles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pain", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tamoxifen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tosyl Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triazoles", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Professorial Unit of Medical Oncology, University and National Cancer Research Institute, Largo R. Benzi 10, 16132, Genoa, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boccardo", 
        "givenName": "Francesco", 
        "id": "sg:person.0673614133.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673614133.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Professorial Unit of Medical Oncology, University and National Cancer Research Institute, Largo R. Benzi 10, 16132, Genoa, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rubagotti", 
        "givenName": "Alessandra", 
        "id": "sg:person.0631342033.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631342033.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale Sant'Anna", 
          "id": "https://www.grid.ac/institutes/grid.416317.6", 
          "name": [
            "S. Anna Hospital, Como, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Conti", 
        "givenName": "Giario", 
        "id": "sg:person.0621236003.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0621236003.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale San Bortolo", 
          "id": "https://www.grid.ac/institutes/grid.416303.3", 
          "name": [
            "City Hospital, Fidenza, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Potenzoni", 
        "givenName": "Domenico", 
        "id": "sg:person.074515053.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.074515053.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale San Bortolo", 
          "id": "https://www.grid.ac/institutes/grid.416303.3", 
          "name": [
            "City Hospital, Siena, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Manganelli", 
        "givenName": "Antonio", 
        "id": "sg:person.01267432433.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01267432433.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (Italy)", 
          "id": "https://www.grid.ac/institutes/grid.476012.6", 
          "name": [
            "AstraZeneca, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Monaco", 
        "givenName": "Demetrio Del", 
        "id": "sg:person.0643677054.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643677054.16"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0022-5347(05)64652-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003516800"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-198815030-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003719405", 
          "https://doi.org/10.2165/00003088-198815030-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-198815030-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003719405", 
          "https://doi.org/10.2165/00003088-198815030-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/030006058601400309", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009791320"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/030006058601400309", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009791320"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000019526", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024919769"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1078-1439(00)00118-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030725573"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0090-4295(00)00823-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033091427"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-200443130-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042773399", 
          "https://doi.org/10.2165/00003088-200443130-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-200443130-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042773399", 
          "https://doi.org/10.2165/00003088-200443130-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00001813-199601000-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051712212"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00001813-199601000-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051712212"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-200342040-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052002165", 
          "https://doi.org/10.2165/00003088-200342040-00004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-200342040-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052002165", 
          "https://doi.org/10.2165/00003088-200342040-00004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-200342040-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052002165", 
          "https://doi.org/10.2165/00003088-200342040-00004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075221317", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-10", 
    "datePublishedReg": "2005-10-01", 
    "description": "OBJECTIVE: A randomized multicenter (14 centers) trial was conducted in 114 men with prostate cancer to determine whether the antiestrogen tamoxifen ('Nolvadex') 20 mg or the aromatase inhibitor anastrozole ('Arimidex') 1 mg prevent gynecomastia and breast pain during treatment with the non-steroidal antiandrogen bicalutamide ('Casodex') 150 mg, without compromising efficacy, safety, or quality of life. Plasma samples were collected in a subgroup of these patients to investigate whether trough (pre-dose) concentrations of bicalutamide 150 mg are influenced by concomitant administration of tamoxifen 20 mg or anastrozole 1 mg; the results of this pilot study are reported in this article.\nMETHODS: A subpopulation of patients from a randomized placebo-controlled trial evaluating tamoxifen 20 mg and anastrozole 1 mg for the prevention of gynecomastia and breast pain in men receiving bicalutamide 150 mg for early or recurrent prostate cancer were selected on a voluntary basis from three of the trial centers. Plasma samples were collected on days 7, 14, 28, and 84 of therapy and analyzed to determine the plasma concentrations of (R)-bicalutamide and (S)-bicalutamide. In addition, plasma concentrations of tamoxifen, N-desmethyltamoxifen, and anastrozole were determined.\nRESULTS: A total of 21 patients were selected. There was no significant difference between treatment groups with respect to the trough plasma concentrations of either bicalutamide enantiomer at any point during the study. Plasma concentrations of the enantiomers, and the relative proportion of the (R))- and (S)-enantiomers, were consistent with those reported in previous studies. Plasma concentrations of tamoxifen, N-desmethyltamoxifen, and anastrozole were also similar to those described elsewhere in the literature.\nCONCLUSIONS: The findings of this pilot study suggest that trough plasma concentrations of bicalutamide enantiomers following administration of bicalutamide 150 mg are not markedly influenced by concomitant administration of tamoxifen 20 mg or anastrozole 1 mg. However, an effect of tamoxifen on bicalutamide pharmacokinetics can not be completely excluded due to the size of this study. Further studies are needed to clarify the effect of tamoxifen on bicalutamide pharmacokinetics and prostate cancer control in bicalutamide-treated patients. 'Arimidex', 'Casodex', and 'Nolvadex' are trademarks of the AstraZeneca group of companies.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-005-1016-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "56"
      }
    ], 
    "name": "Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer", 
    "pagination": "415-420", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "2a7bda04c4187f6584873ced45d1d16c27fe5833d050042df00404c10e9d3aba"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15838655"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-005-1016-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1008917393"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-005-1016-1", 
      "https://app.dimensions.ai/details/publication/pub.1008917393"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T14:30", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000373_0000000373/records_13093_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00280-005-1016-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-005-1016-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-005-1016-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-005-1016-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-005-1016-1'


 

This table displays all metadata directly associated to this object as RDF triples.

227 TRIPLES      21 PREDICATES      59 URIs      41 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-005-1016-1 schema:about N0b9f1ee16f584ec780f60a5c2696c9e4
2 N20acc7b682f24f9295d4aa76df5a73c9
3 N24681953b74f404e85940fa4428aa99a
4 N24977020f2d549509823f93d5c5cc4c3
5 N2990227215a0497db7dedec8329a3544
6 N314c76b2a5e3411e9cb376bb86e5b65e
7 N6720d796d25249e9b874fc46d2c01b32
8 N67ebf912196a4e5b82f7ce52b950c2ba
9 N823428d2ca6947dc851fc12e3683e609
10 N87b1b5658fa1430788c6cd4019e0ed91
11 N8ab73e20bf3344babd616e092944b358
12 N8d18efcf9c124c3bb2ec5a71e23ed701
13 Nce4be44d60e64e32b8a8e21009d09b91
14 Nd0d45d4449434aae878061c6d4aa89ca
15 Nd19a22d44cc6409794533bff67ad0c1c
16 Nd2d574aed7744efaa0403bdeeb0ade48
17 Ne087ad1ae1c946a0b9d5c5db92b4ef68
18 Ne524ac1f2f4543e7bf6f8ba6144b35e2
19 Nefe138cd84c844d099624592275ffe2b
20 Nf5d5b7ed29b842de85c147d58ab2312d
21 anzsrc-for:11
22 anzsrc-for:1117
23 schema:author Nd9ed19ba591446409a1630434f1af756
24 schema:citation sg:pub.10.2165/00003088-198815030-00003
25 sg:pub.10.2165/00003088-200342040-00004
26 sg:pub.10.2165/00003088-200443130-00003
27 https://app.dimensions.ai/details/publication/pub.1075221317
28 https://doi.org/10.1016/s0022-5347(05)64652-6
29 https://doi.org/10.1016/s0090-4295(00)00823-2
30 https://doi.org/10.1016/s1078-1439(00)00118-6
31 https://doi.org/10.1097/00001813-199601000-00006
32 https://doi.org/10.1159/000019526
33 https://doi.org/10.1177/030006058601400309
34 schema:datePublished 2005-10
35 schema:datePublishedReg 2005-10-01
36 schema:description OBJECTIVE: A randomized multicenter (14 centers) trial was conducted in 114 men with prostate cancer to determine whether the antiestrogen tamoxifen ('Nolvadex') 20 mg or the aromatase inhibitor anastrozole ('Arimidex') 1 mg prevent gynecomastia and breast pain during treatment with the non-steroidal antiandrogen bicalutamide ('Casodex') 150 mg, without compromising efficacy, safety, or quality of life. Plasma samples were collected in a subgroup of these patients to investigate whether trough (pre-dose) concentrations of bicalutamide 150 mg are influenced by concomitant administration of tamoxifen 20 mg or anastrozole 1 mg; the results of this pilot study are reported in this article. METHODS: A subpopulation of patients from a randomized placebo-controlled trial evaluating tamoxifen 20 mg and anastrozole 1 mg for the prevention of gynecomastia and breast pain in men receiving bicalutamide 150 mg for early or recurrent prostate cancer were selected on a voluntary basis from three of the trial centers. Plasma samples were collected on days 7, 14, 28, and 84 of therapy and analyzed to determine the plasma concentrations of (R)-bicalutamide and (S)-bicalutamide. In addition, plasma concentrations of tamoxifen, N-desmethyltamoxifen, and anastrozole were determined. RESULTS: A total of 21 patients were selected. There was no significant difference between treatment groups with respect to the trough plasma concentrations of either bicalutamide enantiomer at any point during the study. Plasma concentrations of the enantiomers, and the relative proportion of the (R))- and (S)-enantiomers, were consistent with those reported in previous studies. Plasma concentrations of tamoxifen, N-desmethyltamoxifen, and anastrozole were also similar to those described elsewhere in the literature. CONCLUSIONS: The findings of this pilot study suggest that trough plasma concentrations of bicalutamide enantiomers following administration of bicalutamide 150 mg are not markedly influenced by concomitant administration of tamoxifen 20 mg or anastrozole 1 mg. However, an effect of tamoxifen on bicalutamide pharmacokinetics can not be completely excluded due to the size of this study. Further studies are needed to clarify the effect of tamoxifen on bicalutamide pharmacokinetics and prostate cancer control in bicalutamide-treated patients. 'Arimidex', 'Casodex', and 'Nolvadex' are trademarks of the AstraZeneca group of companies.
37 schema:genre research_article
38 schema:inLanguage en
39 schema:isAccessibleForFree false
40 schema:isPartOf N1b4be0eb96bd4075a83cdd239ff74d76
41 N7594ec8868b24cff868db6760b1f969d
42 sg:journal.1088364
43 schema:name Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer
44 schema:pagination 415-420
45 schema:productId N6d5b3aa2dce84517abae9834df4aec8d
46 N79e44b712eaf458ebaa5165663b988cc
47 Nacbfe7f255d142278e3c55892786385f
48 Nb98ea39c29734af88b864f09f662a1e6
49 Nc448d365a138417aa9b1d8441e3e6d13
50 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008917393
51 https://doi.org/10.1007/s00280-005-1016-1
52 schema:sdDatePublished 2019-04-11T14:30
53 schema:sdLicense https://scigraph.springernature.com/explorer/license/
54 schema:sdPublisher N9924ed5cbbe94efb9a9048c9dddf2980
55 schema:url http://link.springer.com/10.1007%2Fs00280-005-1016-1
56 sgo:license sg:explorer/license/
57 sgo:sdDataset articles
58 rdf:type schema:ScholarlyArticle
59 N0b9f1ee16f584ec780f60a5c2696c9e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Triazoles
61 rdf:type schema:DefinedTerm
62 N112fdd1b85194e90b339132138264516 rdf:first sg:person.0643677054.16
63 rdf:rest rdf:nil
64 N16d49791c24144c8af87824a860c022f schema:name Professorial Unit of Medical Oncology, University and National Cancer Research Institute, Largo R. Benzi 10, 16132, Genoa, Italy
65 rdf:type schema:Organization
66 N1b4be0eb96bd4075a83cdd239ff74d76 schema:issueNumber 4
67 rdf:type schema:PublicationIssue
68 N20acc7b682f24f9295d4aa76df5a73c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Nitriles
70 rdf:type schema:DefinedTerm
71 N24681953b74f404e85940fa4428aa99a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Anilides
73 rdf:type schema:DefinedTerm
74 N24977020f2d549509823f93d5c5cc4c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Drug Interactions
76 rdf:type schema:DefinedTerm
77 N2990227215a0497db7dedec8329a3544 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Antineoplastic Agents, Hormonal
79 rdf:type schema:DefinedTerm
80 N314c76b2a5e3411e9cb376bb86e5b65e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Chromatography, High Pressure Liquid
82 rdf:type schema:DefinedTerm
83 N477fe24b93444ab98e60b64649c05e52 rdf:first sg:person.0631342033.94
84 rdf:rest Ne6c1a64f6752485b92a4f30dbef76b75
85 N6720d796d25249e9b874fc46d2c01b32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Aromatase Inhibitors
87 rdf:type schema:DefinedTerm
88 N67ebf912196a4e5b82f7ce52b950c2ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Male
90 rdf:type schema:DefinedTerm
91 N6d5b3aa2dce84517abae9834df4aec8d schema:name pubmed_id
92 schema:value 15838655
93 rdf:type schema:PropertyValue
94 N7067d90050b04371ac3f65e703fa4681 rdf:first sg:person.074515053.61
95 rdf:rest N830824505f9e47f4a91686f821e8b163
96 N7594ec8868b24cff868db6760b1f969d schema:volumeNumber 56
97 rdf:type schema:PublicationVolume
98 N79e44b712eaf458ebaa5165663b988cc schema:name dimensions_id
99 schema:value pub.1008917393
100 rdf:type schema:PropertyValue
101 N823428d2ca6947dc851fc12e3683e609 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Double-Blind Method
103 rdf:type schema:DefinedTerm
104 N830824505f9e47f4a91686f821e8b163 rdf:first sg:person.01267432433.40
105 rdf:rest N112fdd1b85194e90b339132138264516
106 N87b1b5658fa1430788c6cd4019e0ed91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Middle Aged
108 rdf:type schema:DefinedTerm
109 N8ab73e20bf3344babd616e092944b358 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Prostatic Neoplasms
111 rdf:type schema:DefinedTerm
112 N8d18efcf9c124c3bb2ec5a71e23ed701 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Humans
114 rdf:type schema:DefinedTerm
115 N9924ed5cbbe94efb9a9048c9dddf2980 schema:name Springer Nature - SN SciGraph project
116 rdf:type schema:Organization
117 Nacbfe7f255d142278e3c55892786385f schema:name nlm_unique_id
118 schema:value 7806519
119 rdf:type schema:PropertyValue
120 Nb98ea39c29734af88b864f09f662a1e6 schema:name readcube_id
121 schema:value 2a7bda04c4187f6584873ced45d1d16c27fe5833d050042df00404c10e9d3aba
122 rdf:type schema:PropertyValue
123 Nc0345baa47e34434b4beb97c4a2a4109 schema:name Professorial Unit of Medical Oncology, University and National Cancer Research Institute, Largo R. Benzi 10, 16132, Genoa, Italy
124 rdf:type schema:Organization
125 Nc448d365a138417aa9b1d8441e3e6d13 schema:name doi
126 schema:value 10.1007/s00280-005-1016-1
127 rdf:type schema:PropertyValue
128 Nce4be44d60e64e32b8a8e21009d09b91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Anastrozole
130 rdf:type schema:DefinedTerm
131 Nd0d45d4449434aae878061c6d4aa89ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Pain
133 rdf:type schema:DefinedTerm
134 Nd19a22d44cc6409794533bff67ad0c1c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Tamoxifen
136 rdf:type schema:DefinedTerm
137 Nd2d574aed7744efaa0403bdeeb0ade48 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Androgen Antagonists
139 rdf:type schema:DefinedTerm
140 Nd9ed19ba591446409a1630434f1af756 rdf:first sg:person.0673614133.08
141 rdf:rest N477fe24b93444ab98e60b64649c05e52
142 Ne087ad1ae1c946a0b9d5c5db92b4ef68 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Aged, 80 and over
144 rdf:type schema:DefinedTerm
145 Ne524ac1f2f4543e7bf6f8ba6144b35e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Tosyl Compounds
147 rdf:type schema:DefinedTerm
148 Ne6c1a64f6752485b92a4f30dbef76b75 rdf:first sg:person.0621236003.77
149 rdf:rest N7067d90050b04371ac3f65e703fa4681
150 Nefe138cd84c844d099624592275ffe2b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Gynecomastia
152 rdf:type schema:DefinedTerm
153 Nf5d5b7ed29b842de85c147d58ab2312d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Aged
155 rdf:type schema:DefinedTerm
156 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
157 schema:name Medical and Health Sciences
158 rdf:type schema:DefinedTerm
159 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
160 schema:name Public Health and Health Services
161 rdf:type schema:DefinedTerm
162 sg:journal.1088364 schema:issn 0344-5704
163 1432-0843
164 schema:name Cancer Chemotherapy and Pharmacology
165 rdf:type schema:Periodical
166 sg:person.01267432433.40 schema:affiliation https://www.grid.ac/institutes/grid.416303.3
167 schema:familyName Manganelli
168 schema:givenName Antonio
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01267432433.40
170 rdf:type schema:Person
171 sg:person.0621236003.77 schema:affiliation https://www.grid.ac/institutes/grid.416317.6
172 schema:familyName Conti
173 schema:givenName Giario
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0621236003.77
175 rdf:type schema:Person
176 sg:person.0631342033.94 schema:affiliation N16d49791c24144c8af87824a860c022f
177 schema:familyName Rubagotti
178 schema:givenName Alessandra
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631342033.94
180 rdf:type schema:Person
181 sg:person.0643677054.16 schema:affiliation https://www.grid.ac/institutes/grid.476012.6
182 schema:familyName Monaco
183 schema:givenName Demetrio Del
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643677054.16
185 rdf:type schema:Person
186 sg:person.0673614133.08 schema:affiliation Nc0345baa47e34434b4beb97c4a2a4109
187 schema:familyName Boccardo
188 schema:givenName Francesco
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673614133.08
190 rdf:type schema:Person
191 sg:person.074515053.61 schema:affiliation https://www.grid.ac/institutes/grid.416303.3
192 schema:familyName Potenzoni
193 schema:givenName Domenico
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.074515053.61
195 rdf:type schema:Person
196 sg:pub.10.2165/00003088-198815030-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003719405
197 https://doi.org/10.2165/00003088-198815030-00003
198 rdf:type schema:CreativeWork
199 sg:pub.10.2165/00003088-200342040-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052002165
200 https://doi.org/10.2165/00003088-200342040-00004
201 rdf:type schema:CreativeWork
202 sg:pub.10.2165/00003088-200443130-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042773399
203 https://doi.org/10.2165/00003088-200443130-00003
204 rdf:type schema:CreativeWork
205 https://app.dimensions.ai/details/publication/pub.1075221317 schema:CreativeWork
206 https://doi.org/10.1016/s0022-5347(05)64652-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003516800
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1016/s0090-4295(00)00823-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033091427
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1016/s1078-1439(00)00118-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030725573
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1097/00001813-199601000-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051712212
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1159/000019526 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024919769
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1177/030006058601400309 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009791320
217 rdf:type schema:CreativeWork
218 https://www.grid.ac/institutes/grid.416303.3 schema:alternateName Ospedale San Bortolo
219 schema:name City Hospital, Fidenza, Italy
220 City Hospital, Siena, Italy
221 rdf:type schema:Organization
222 https://www.grid.ac/institutes/grid.416317.6 schema:alternateName Ospedale Sant'Anna
223 schema:name S. Anna Hospital, Como, Italy
224 rdf:type schema:Organization
225 https://www.grid.ac/institutes/grid.476012.6 schema:alternateName AstraZeneca (Italy)
226 schema:name AstraZeneca, Milan, Italy
227 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...